Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBVATS
NCT07393386Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine hydrochloride 0.75% injection in postoperative pain (3 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Area Under the Curve of Pain Intensity During Coughing at 48 hours. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07393386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393386.